Tankertanker DesignTankertanker Design非小细胞肺癌EGFR-TKIs 靶向治疗研究进展福建省肿瘤医院 黄 诚Tankertanker DesignTankertanker DesignIPASS 开启了EGFR-TKI 的肺癌精准医学时代0 4 8 12 16 20 240.00.20.40.60.81.0Gefitinib EGFR M+ (n=132)Gefitinib EGFR M- (n=91)Carboplatin / paclitaxel EGFR M+ (n=129)Carboplatin / paclitaxel EGFR M- (n=85)Probabilityof PFSEGFR M+ HR (95% CI) 0.48 (0.36, 0.64), p0.0001EGFR M- HR (95% CI) 2.85 (2.05, 3.98), p0.0001Primary Cox analysis with covariates; ITT population; HR 1 implies a lower risk of progres
